The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$163.01

Today's change+3.63 +2.28%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$163.01

Today's change+3.63 +2.28%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up sharply

Valeant Pharmaceuticals International Inc closed up sharply Wednesday, rallying $3.63 or 2.28% to $163.01. Over the last five days, shares have gained 2.86% and are currently 4.36% off of the 52-week high. Shares have outperformed the S&P TSX by 32.72% during the last year.

Key company metrics

  • Trailing P/E94.51×
  • P/E 1 year forward18.91×
  • Forward PEG0.71×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS$1.72
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.25%

Based on its net profit margin of 6.25%, Valeant Pharmaceuticals International Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.54%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue2,0562,0411,8862,064
Total other revenue--------
Total revenue2,0562,0411,8862,064
Gross profit1,4951,4561,3681,332
Total cost of revenue561586518732
Total operating expense1,3721,6861,6231,876
Selling / general / administrative504516482450
Research & development59676160
Depreciation / amortization393366355204
Interest expense (income), net operating--------
Unusual expense (income)87153250351
Other operating expenses, total-2320-4379
Operating income684355263188
Interest income (expense), net non-operating-258-241-247-263
Gain (loss) on sale of assets--------
Other--------
Income before tax3771215-78
Income after tax276122-20125
Income tax, total100-125-203
Net income275126-23124
Total adjustments to net income--------
Net income before extra. items275126-23124
Minority interest-14-2-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items275126-23124
Inc. avail. to common incl. extra. items275126-23124
Diluted net income275126-23124
Dilution adjustment0000
Diluted weighted average shares341341335335
Diluted EPS excluding extraordinary itemsvalue per share0.810.37-0.070.37
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.010.670.431.08